Skip to main content

Table 2 Patient demographics and tumor characteristics in the fractionated BNCT clinical trial

From: Clinical trials for treating recurrent head and neck cancer with boron neutron capture therapy using the Tsing-Hua Open Pool Reactor

Patient no.

Age

Sex

Primary site

Histopathology

Accumulated dose of prior RT (Gy)

Recurrent stage

Tumor diameter (cm)

1

68

M

Hypopharynx

SCC

136.4 in 2 courses

T1N2a

4

2

67

M

Tongue

SCC

66

T2N2a

9.5

3

49

F

Nasal cavity

Sinonasal carcinoma

120 in 2 courses

T4N0

5

4

71

M

Gingiva

SCC

66

T4N0

7.5

5

46

M

Nasopharynx

Undifferentiated ca

136 in 2 courses

T4N0

3.9

6

58

F

Nasopharynx

Non-keratinizing ca

122 in 2 courses

T3N0

2.5

7

57

M

Tongue

SCC

70

T3N0

4.5

8

52

M

Tongue

SCC

70

T4aN0

5.3

9

54

M

Maxillary sinus

SCC

70

T3N0

8.9

10

54

M

Tongue

SCC

63

T0N2b

6.0

11

48

M

Tongue

Spindle cell sarcoma

107 in 2 courses

T4bN0

6.0

12

74

M

Maxillary sinus

SCC

105 in 2 courses

T2N0

3.5

13

51

M

Parotid gland

Adenocarcinoma

136 in 2 courses

T4N0

5.8

14

56

M

Buccal mucosa

SCC

125.9 in 2 courses

T1N0

0.9

15

40

M

Hypopharynx

SCC

95 in 2 courses

T3N0

4.7

16

59

M

Nasopharynx

Non-keratinizing ca

136 in 2 courses

T3N0

3.9

17

62

M

Buccal mucosa

SCC

64

T4aN0

6.4

  1. BNCT boron neutron capture therapy, SCC squamous cell carcinoma